The goal of this trial is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease. Parts 1-4 complete, Part 5 (multiple doses in patients with Parkinson's Disease) in progress.
Male and female participants aged ≥ 40 to ≤ 75 years.
Body mass index (BMI) between 18 and 34.0 kg/m2, inclusive.
If being treated with selective serotonin reuptake inhibitors (SSRIs) for anxiety/ depression, must be on a stable dose for 60 days prior to Day -1 and must remain on that dose for the remainder of the study.
Must have had other causes of Parkinsonism excluded
A clinically significant history of gastrointestinal disorders or any significant medical conditions that would be likely to influence IMP absorption, or evidence of clinically significant central nervous system, respiratory, cardiovascular or metabolic dysfunction or other significant medical conditions with potential to impact participant safety or hinder interpretation of study results.
Clinically significant neurologic disorder other than PD, including history of stroke within 12 months of Screening, seizure within 5 years of Screening, or head trauma with loss of consciousness within 6 months of Screening.
Those with known PD risk genes (per medical history).
Reside in a nursing home or assisted care facility.
Mission Therapeutics
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Collaborator
Parkinson's UK
Collaborator